Demographics and clinical characteristics of 133 patients
| Characteristics | D1 cohort (n=59) | D2 cohort (n=59) | D3 cohort (n=15) | P value | |
| Sex, n (%) | Male | 28 (47) | 31 (53) | 14 (93) | 0.0035 |
| Female | 31 (53) | 28 (47) | 1 (7) | ||
| Age, median (range) | 68 (48–89) | 68 (50–84) | 72 (60–82) | ||
| Race, n (%) | White | 41 (69) | 52 (88) | 14 (93) | 0.018 |
| Black | 18 (31) | 7 (12) | 1 (7) | ||
| Smoking, n (%) | Never | 2 (3) | 2 (3) | 13 (87) | <0.0001 |
| Former/current | 57 (97) | 57 (97) | 2 (13) | ||
| Stage, n (%) | IIIA | 34 (58) | 23 (39) | 10 (67) | 0.125 |
| IIIB | 20 (34) | 32 (54) | 4 (27) | ||
| IIIC | 5 (8) | 4 (7) | 1 (6) | ||
| Histology, n (%) | Adenocarcinoma | 28 (47) | 29 (49) | 10 (67) | 0.762 |
| Squamous cell carcinoma | 28 (47) | 27 (46) | 5 (33) | ||
| Large cell carcinoma | 3 (6) | 3 (5) | 0 | ||
| Median follow-up (PFS) | Months | 14.5 (0.23–30.2) | 14.9 (1.6–30.5) | 10.5 (0.2–34.8) | |
| Median follow-up (OS) | Months | 16.5 (3.4–30.2) | 16.5 (2.5–30.5) | 10.5 (0.2–35.7) | |
OS, overall survival; PFS, progression-free survival.